Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. more
Time Frame | IMVT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.56% | -0.33% | -1.49% |
1-Month Return | -3.01% | -4.57% | -0.37% |
3-Month Return | -9.44% | -9.96% | 3.89% |
6-Month Return | -4.71% | -5.67% | 9.34% |
1-Year Return | -40.98% | 2.53% | 25.19% |
3-Year Return | 232.65% | -1.43% | 24.7% |
5-Year Return | 64.54% | 34.73% | 85.39% |
10-Year Return | 162.11% | 102.14% | 187.19% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Cost of Revenue | 21.00K | 998.00K | 1.23M | 1.32M | 231.00K | [{"date":"2020-03-31","value":1.59,"profit":true},{"date":"2021-03-31","value":75.38,"profit":true},{"date":"2022-03-31","value":93.05,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":17.45,"profit":true}] |
Gross Profit | (21.00K) | (998.00K) | (1.23M) | (1.32M) | (231.00K) | [{"date":"2020-03-31","value":-2100000,"profit":false},{"date":"2021-03-31","value":-99800000,"profit":false},{"date":"2022-03-31","value":-123200000,"profit":false},{"date":"2023-03-31","value":-132400000,"profit":false},{"date":"2024-03-31","value":-23100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Operating Expenses | 66.08M | 108.12M | 156.03M | 208.28M | 282.71M | [{"date":"2020-03-31","value":23.37,"profit":true},{"date":"2021-03-31","value":38.24,"profit":true},{"date":"2022-03-31","value":55.19,"profit":true},{"date":"2023-03-31","value":73.67,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Operating Income | (65.67M) | (107.79M) | (156.16M) | (198.47M) | (282.71M) | [{"date":"2020-03-31","value":-6566600000,"profit":false},{"date":"2021-03-31","value":-10778900000,"profit":false},{"date":"2022-03-31","value":-15615900000,"profit":false},{"date":"2023-03-31","value":-19846900000,"profit":false},{"date":"2024-03-31","value":-28270900000,"profit":false}] |
Total Non-Operating Income/Expense | (1.25M) | 328.00K | (781.00K) | 4.90M | 48.89M | [{"date":"2020-03-31","value":-2.56,"profit":false},{"date":"2021-03-31","value":0.67,"profit":true},{"date":"2022-03-31","value":-1.6,"profit":false},{"date":"2023-03-31","value":10.03,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Pre-Tax Income | (66.29M) | (107.79M) | (156.81M) | (210.95M) | (258.77M) | [{"date":"2020-03-31","value":-6629100000,"profit":false},{"date":"2021-03-31","value":-10778900000,"profit":false},{"date":"2022-03-31","value":-15681400000,"profit":false},{"date":"2023-03-31","value":-21095100000,"profit":false},{"date":"2024-03-31","value":-25876900000,"profit":false}] |
Income Taxes | 97.00K | (358.00K) | (84.00K) | 9.00K | 567.00K | [{"date":"2020-03-31","value":17.11,"profit":true},{"date":"2021-03-31","value":-63.14,"profit":false},{"date":"2022-03-31","value":-14.81,"profit":false},{"date":"2023-03-31","value":1.59,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Income After Taxes | (66.39M) | (107.43M) | (156.73M) | (210.96M) | (259.34M) | [{"date":"2020-03-31","value":-6638800000,"profit":false},{"date":"2021-03-31","value":-10743100000,"profit":false},{"date":"2022-03-31","value":-15673000000,"profit":false},{"date":"2023-03-31","value":-21096000000,"profit":false},{"date":"2024-03-31","value":-25933600000,"profit":false}] |
Income From Continuous Operations | (66.39M) | (107.43M) | (156.73M) | (210.96M) | (259.34M) | [{"date":"2020-03-31","value":-6638800000,"profit":false},{"date":"2021-03-31","value":-10743100000,"profit":false},{"date":"2022-03-31","value":-15673000000,"profit":false},{"date":"2023-03-31","value":-21096000000,"profit":false},{"date":"2024-03-31","value":-25933600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | (66.39M) | (107.43M) | (156.73M) | (210.96M) | (259.34M) | [{"date":"2020-03-31","value":-6638800000,"profit":false},{"date":"2021-03-31","value":-10743100000,"profit":false},{"date":"2022-03-31","value":-15673000000,"profit":false},{"date":"2023-03-31","value":-21096000000,"profit":false},{"date":"2024-03-31","value":-25933600000,"profit":false}] |
EPS (Diluted) | (0.90) | (1.24) | (1.43) | (1.71) | (1.90) | [{"date":"2020-03-31","value":-90,"profit":false},{"date":"2021-03-31","value":-124,"profit":false},{"date":"2022-03-31","value":-143,"profit":false},{"date":"2023-03-31","value":-171,"profit":false},{"date":"2024-03-31","value":-190,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IMVT | |
---|---|
Cash Ratio | 7.10 |
Current Ratio | 7.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IMVT | |
---|---|
ROA (LTM) | -54.54% |
ROE (LTM) | -92.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IMVT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.13 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.87 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IMVT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 8.42 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Immunovant Inc (IMVT) share price today is $26.08
Yes, Indians can buy shares of Immunovant Inc (IMVT) on Vested. To buy Immunovant Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMVT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Immunovant Inc (IMVT) via the Vested app. You can start investing in Immunovant Inc (IMVT) with a minimum investment of $1.
You can invest in shares of Immunovant Inc (IMVT) via Vested in three simple steps:
The 52-week high price of Immunovant Inc (IMVT) is $45.58. The 52-week low price of Immunovant Inc (IMVT) is $24.61.
The price-to-earnings (P/E) ratio of Immunovant Inc (IMVT) is
The price-to-book (P/B) ratio of Immunovant Inc (IMVT) is 8.42
The dividend yield of Immunovant Inc (IMVT) is 0.00%
The market capitalization of Immunovant Inc (IMVT) is $3.78B
The stock symbol (or ticker) of Immunovant Inc is IMVT